News & Views
Agreement to Advance Preclinical Services
Oct 22 2020
US Biotech Applied StemCell, has signed a licencing agreement with Dublin-based ERS Genomics for use of its CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, for developing its preclinical research tools, including cell and animal model generation, antibody discovery and preclinical assay services to support cell and gene product development.
“Applied StemCell has been a leading stem cell company I have followed for many years," said Eric Rhodes, CEO of ERS Genomics. “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."
“We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,” added Ruby Tsai, CEO of Applied StemCell.
Financial details of the agreement were not disclosed.
More information online
Digital Edition
Labmate UK & Ireland 49.2 - March 2024
March 2024
In This Edition Articles - Choosing the right LIMS for your lab: Four key considerations - Pay increases to continue but staff focus on security and training - Building a global culture of...
View all digital editions
Events
Mar 26 2024 Milan, Italy
Mar 27 2024 Lyon, France
Microbiology Society Annual Conference 2024
Apr 08 2024 Edinburgh 2024
Apr 09 2024 Munich, Germany
Apr 10 2024 Helsinki, Finland